<DOC>
	<DOCNO>NCT00616655</DOCNO>
	<brief_summary>To determine safety efficacy SEP-225441 ( eszopiclone ) subject generalized anxiety disorder ( GAD ) .</brief_summary>
	<brief_title>Generalized Anxiety Disorder Proof Concept Efficacy Safety Study SEP-225441 ( Eszopiclone ) In GAD Subjects</brief_title>
	<detailed_description>This multicenter , randomize , double blind , placebo control study safety efficacy SEP-225441 ( eszopiclone ) male female adult subject diagnosis generalize anxiety disorder ( GAD ) . The study consist screen period 7-10 day , 8 week treatment , 7 day follow-up period . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Male female subject must 18 50 year age Subjects must GAD Subjects must otherwise good general health Subject document history HIV , hepatitis B hepatitis C. Subject recent history ( within 6 month study entry ) current diagnosis Major Depressive Disorder , panic disorder ( 3 panic attack past month ) . Post Traumatic Stress Disorder , body dysmorphic disorder , eat disorder , disorder . Subject history presence ObsessiveCompulsive Disorder ( OCD ) , psychotic , bipolar schizophrenic disorder . Subject presence history antisocial personality severe disorder Subject refractory GAD ( previously unresponsive 2 adequate course SSRI , SNRI , benzodiazepine nonbenzodiazepine treatment GAD ) . Subject history seizure , include febrile seizure . Subject initiate psychotherapeutic intervention 30 day ; however , continue psychotherapy allow stable specifically direct GAD . Subject undergo undergone electroconvulsive therapy . Subject current smoker smoke within last 12 month . Subject donate blood within past 30 day plan donate within 30 day study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Anxiety</keyword>
</DOC>